This article was originally meant to be a straightforward look at a natural compound called SAM-e, a substance that has been studied, intermittently, for mood disorders. It seemed like a reasonable and uncomplicated topic.

SAM-e does not force neurotransmitter release or carry the same dependency risks associated with many psychiatric drugs, and I thought that alone made it worth examining. But as I started writing, I kept getting pulled off course.

Not because of SAM-e, but because it represents something that is truly missing in the world of mental health medicine.

That realization reshaped this article. SAM-e became less interesting than the question it raised: why do safer, less toxic, or more biologically grounded approaches remain marginal, while powerful, dependency-forming drugs dominate mental health care?

I have seen the failures of mental health medication up close, not in abstracts or clinical summaries, but in my own family. I have watched well-intentioned treatments turn into long-term dependencies. I have seen drugs prescribed to ease anxiety or improve focus end up doing the opposite, creating new problems layered on top of the original ones. Once you’ve watched that happen, it becomes difficult to write neutrally about the system that produced it.

We now live in a system where psychiatric medications are prescribed early, often indefinitely, and with remarkably little discussion of long-term consequences or exit strategies. Managing symptoms has taken precedence over healing. Dependence has quietly become part of the deal. Approaches that fall outside this model are rarely explored with the same seriousness, not because they have been conclusively ruled out, but because they do not fit the prevailing business logic.

Every generation seems to get its own pharmaceutical answer to anxiety, depression, and the inability to cope with modern life. The drugs change. The language changes. The marketing changes. The underlying business model does not. It has always been addiction.

For your grandparents or great-grandparents, that drug was Valium.

The Little Yellow Pill

Valium, the “Mother’s Little Helper”, as The Rolling Stones called it, was introduced in the 1960s and quickly became one of the most widely prescribed drugs in the world. It was sold as safe, modern, and effective. Anxiety, depression, stress, trouble sleeping? Valium was the answer. Doctors prescribed it freely. Patients stayed on it for years.

When it stopped working, the dose went up. When symptoms returned, more pills were added. Tolerance was expected. Dependence was not considered a problem. It was simply part of the routine.

Only later did the consequences become impossible to ignore. Cognitive impairment. Emotional flattening. Increased depression and worsening anxiety between doses. Severe withdrawal syndromes that could last months or longer. Many people who initially sought help found themselves trapped in something far worse: benzodiazepine dependence. Valium did not cure anxiety or depression, it created a new condition layered on top of the original one.

The lesson should have been a lasting one. Instead, it was largely forgotten.

Adderall: Meth’s Legal Cousin

Fast forward, and the pattern is unmistakable.

Amphetamine-based stimulants like Adderall have been a standard treatment for attention disorders for decades. This is not a new experiment or a temporary trend. It is a deeply entrenched paradigm. Children are started early. Adults remain on these drugs indefinitely. Long-term use is not an exception. It is the expectation.

The mechanism is different from Valium, but the logic is the same. Amphetamines force the brain into a heightened state of dopamine and norepinephrine activity. Focus improves. Energy increases. Tasks get done. On paper, the drug “works.”

But the brain adapts.

Over time, tolerance develops. Sleep deteriorates. Appetite disappears. Anxiety increases. Emotional volatility creeps in. Many people find that the very drug meant to help them function begins to generate its own symptoms: restlessness, irritability, panic, and low mood when the drug wears off.

What began as treatment for attention problems often becomes a driver of anxiety and depression.

This is the central failure of the model. A drug intended to treat mental health conditions frequently exacerbates the very problems it claims to address.

Anxious people become more anxious. Depressed people experience sharper emotional crashes. Attention may improve, but at the cost of nervous system instability. When patients try to stop, withdrawal can be brutal: fatigue, brain fog, emotional collapse, inability to concentrate at all. At that point, restarting the drug feels less like a choice and more like survival.

No Exit, No Innovation

As with Valium, the system rarely takes responsibility for this outcome.

There is little discussion of how long stimulant treatment is meant to last. Little guidance on tapering. Little acknowledgment that withdrawal itself can be prolonged and disabling. Patients are often left to navigate these realities alone, years or decades into treatment.

What makes this especially disturbing is how little has changed. Despite decades of prescribing and billions of dollars in revenue, mental health care remains locked into the same basic strategy: force the brain into compliance. The drugs change names. Delivery systems are refined. But the underlying approach is unchanged.

That stagnation is not accidental. It is profitable.

This is how entrenched drug markets behave. Once a model generates steady revenue, it defends itself. Criticism is dismissed. Harms are reframed as “side effects” or individual sensitivity. Alternatives that do not fit the model are sidelined or ignored. The possibility that the paradigm itself is flawed is rarely taken seriously.

Then, as now, most doctors were not malicious. Many genuinely believed they were helping. But good intentions do not erase systemic harm. When a treatment creates dependence, amplifies symptoms, and leaves people worse off when they try to stop, something has gone fundamentally wrong.

Mental health care should reduce suffering, not compound it. It should stabilize lives, not lock people into cycles of dependence. And it should never treat addiction as an acceptable byproduct of care.

Valium did not cure anxiety.

Amphetamines do not cure attention disorders.

They manage symptoms temporarily while often creating new ones that keep people tethered to the drug. Different decades. Different labels. Same trap.

What this history makes clear is that we are not dealing with isolated mistakes. We are dealing with a system that repeatedly chooses powerful, dependency-forming drugs over slower, safer, and more biologically grounded approaches. When harm becomes undeniable, the drug falls out of favor, only to be replaced by another version of the same idea.

What is needed now is not another generation of the same medications, but serious investment in less toxic, more natural, and genuinely restorative ways to address mental health. That means funding research not driven solely by patent potential, asking harder questions about long-term outcomes, and admitting that managing symptoms indefinitely is not the same as healing.